Neurocrine Biosciences, Inc.
https://www.neurocrine.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Neurocrine Biosciences, Inc.
Bayer Returns To Cancer Drug In-Licensing With NextRNA Deal
Oncology is key to the German group’s turnaround plans and an early-stage licensing pact with NextRNA is the first cancer deal by its new business development leader.
Neurocrine’s Phase II Results In Schizophrenia Mixed, But Enough To Move To Phase III
Competing against Bristol and AbbVie in the muscarinic receptor agonist space, Neurocrine’s drug shows efficacy but a high placebo response and no dose effect.
Advanz Adds Biosimilars Alliance With Alkem’s Enzene
Advanz Pharma has further built out its biosimilars interests by striking a deal with Alkem’s Enzene Biosciences subsidiary to develop and commercialize a rare disease treatment.
Five Recent Deals Show ADCs Aren’t Cooling Off For Summer
While 2024 has seen two buyouts of antibody-drug conjugate specialists with $1bn-plus price tags, the focus on ADCs has continued, accounting for almost half of recent oncology deals.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice